Press release excerpt: “Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling Initial Data from Cohort 1 to be Reported in December 2024 Highlights Recently Presented Insights on Pediatric MYBPC3-associated HCM Disease Burden SOUTH SAN FRANCISCO, Calif.,
Gene Therapy
Cardiomyopathy Study Participants Needed for 5 Minute Survey
Are you affected by cardiomyopathy? Please CLICK HERE to access a 5-10 minute survey. Learn more below. CureHeart is developing genetic therapies to treat inherited cardiomyopathy. https://cureheart.org/patients The CureHeart project brings together researchers across the UK, US and Asia, and commercial as well as patient advocacy partners, to develop effective genetic therapies for cardiomyopathies. The
Read More… from Cardiomyopathy Study Participants Needed for 5 Minute Survey
Gene Therapy for the Heart
What is gene therapy and how might it be used for heart disease? In the past few decades, through the efforts of dedicated researchers around the world and initiatives like the Human Genome Project, we have a much better understanding of how variations in our genes can cause or contribute to disease. Nearly 100 disease-associated
New Potential Targets for Gene Therapy in Heart Failure Patients
New targets for gene therapy may have been identified by researchers at Harvard Medical School and Brigham and Women’s Hospital. They studied the specific cell changes that lead to heart failure diseases like dilated cardiomyopathy. “Our findings hold enormous potential for rethinking how we treat heart failure and point to the importance of understanding its
Read More… from New Potential Targets for Gene Therapy in Heart Failure Patients
DCM Gene Therapy Advancement at Tenaya Therapeutics
Learn about the basics of DCM genetics and the future of DCM gene therapy.
Read More… from DCM Gene Therapy Advancement at Tenaya Therapeutics
Advancements in Gene Therapy Manufacturing
By creating scientific forums to foster collaboration and creativity, Tenaya Therapeutics has been able to optimize gene therapy manufacturing. Such advancements can help make gene therapy more accessible and affordable for larger patient populations. Read the full article here: https://www.cellandgenecollaborative.com/doc/the-ties-that-bind-engineering-a-cgt-manufacturing-centric-culture-0001
BAG3 Mutation Discovery & Gene Therapy Development
The following documentary film demonstrates the discovery of the BAG 3 genetic mutation that can cause DCM and the development of the gene therapy that became Renovacor. Please click here to view the video to learn more: https://vimeo.com/173290791
Read More… from BAG3 Mutation Discovery & Gene Therapy Development